PIK3CA Mutation

CI-VAR-00002666Explore in graph →CIViC 311

Curated evidence

Evidence by cancer (54 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 51–54 of 54 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
PIK3CA Mutation	Taselisib	Predictive	C	Does Not Support Sensitivity Response	3	accepted	EID11679 In this phase II NCI-MATCH trial subprotocol I, 61 patients harbouring activating PIK3CA mutations were treated with taselisib. The cohort didn't include any patients with breast or squamous cell lung… (full text at CIViC) PMID 35138919 · Krop et al., 2022 · Open in CIViC	civic
Malignant Thyroid Gland Neoplasm1
PIK3CA Mutation	Akt Inhibitor MK2206	Predictive	D	Supports Sensitivity Response	2	submitted	EID12720 In thyroid cancer cell lines, MK2206 selectively inhibited the proliferation of cells harboring PI3K/Akt pathway activating mutations (PIK3CA, PTEN, RAS or RET/PTC) with IC50 values mostly below or ar… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Solid Neoplasm1
MTOR Mutation OR PIK3CA Mutation OR PTEN Mutation OR AKT1 Mutation OR AKT2 Mutation	Sapanisertib	Predictive	B	Supports Sensitivity Response	2	accepted	EID12075 In this study, 30 patients with advanced solid malignancies harboring mTOR/AKT/PI3K pathway alterations were treated with Sapanisertib. The tumor types included sarcomas, breast, ovarian, head and nec… (full text at CIViC) PMID 38126764 · Subbiah et al., 2024 · Open in CIViC	civic

Estrogen Receptor-positive Breast Cancer1unmapped disease
PIK3CA Mutation	Tamoxifen	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID6189 This was a Swedish study of 270 breast tumors removed from patients with unilateral operable breast cancer, and either lymph node metastases or a tumor diameter >30mm. PIK3CA missense mutations were f… (full text at CIViC) PMID 17575221 · Pérez-Tenorio et al., 2007 · Open in CIViC	civic